Modern understanding of causes of death from human immunodeficiency virus infection (literature review)

The human immunodeficiency virus epidemic has remained a global public health challenge for over 40 years. The use of effective antiretroviral therapy has significantly reduced mortality and morbidity. The reduction of human immunodeficiency virus viremia greatly improves the health status of infected individuals. However, widespread use of effective antiretroviral therapy has not resulted in a sufficiently low mortality rate. The profile of causes of death has shifted – among patients on therapy, there has been an increase in fatal cardiovascular events and non-acquired immunodeficiency syndrome related cancers, while acquired immunodeficiency syndrome related deaths still occur among those who have never started treatment or have poor adherence and drug resistance. Most studies have focused on acquired immunodeficiency syndrome related mortality. Few studies address other causes of human immunodeficiency virus -related death, highlighting preventable mortality among people living with human immunodeficiency virus. Cohort studies reveal a significant and persistent gap in life expectancy between people living with human immunodeficiency viru and the uninfected population, especially in key affected groups. Thus, human immunodeficiency virus infection management is a dynamic process influenced by multiple factors. The ultimate goal of this process for infected individuals is to increase both life expectancy and quality of life. Analyzing causes of death can provide essential insights for optimizing human immunodeficiency virus infection control strategies.

1. Kumssa T.H., Mulu A., Mihret A., Asfaw Z.G. Competing risks multi-state model for time-to-event data analysis of HIV/AIDS: a retrospective cohort national datasets, Ethiopia // BMC Infect Dis.- 2024.- vol.24(1). – p.1412. doi: 10.1186/s12879-024-10280-9.

2. Croxford S.E., Martin V., Lucas S.B., et al. Recommendations for defining preventable HIV-related mortality for public health monitoring in the era of Getting to Zero: an expert consensus // Lancet HIV. – 2023.- vol.10(3) – e195-e201. doi: 10.1016/S2352-3018(22)00363-0.

3. Weber R., Ruppik M., Rickenbach M., et al. Swiss HIV Cohort Study (SHCS). Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study // HIV Med. – 2013 –p.195-207. doi: 10.1111/j.1468-1293.2012.01051.x.

4. Trickey A., May M.T., Vehreschild J., et al.; Antiretroviral Therapy Cohort Collaboration (ART-CC). Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy// PLoS One. – 2016.- vol.11(8).- e0160460. doi: 10.1371/journal.pone.0160460.

5. Wada N., Jacobson L.P., Cohen M. et al. Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008 // Am J Epidemiol. – 2013.- vol.177(2). –p.116-25. doi: 10.1093/aje/kws321.

6. Mashiri C.E., Batidzirai J.M., Chifurira R., Chinhamu K. Investigating the Determinants of Mortality before CD4 Count Recovery in a Cohort of Patients Initiated on Antiretroviral Therapy in South Africa Using a Fine and Gray Competing Risks Model // Trop Med Infect Dis. – 2024.-vol.9(7).- p.154. doi: 10.3390/tropicalmed9070154.

7. Roca B. Epidemiological and clinical characteristics of HIV infection in the Spanish VACH Cohort: a descriptive study // Epidemiol Prev. – 2022.-vol.46(1-2). –p.77-83. doi: 10.19191/EP22.1-2.P077.015.

8. Trickey A., McGinnis K., Gill M.J., Abgrall S., et al. JAC. Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies // Lancet HIV. – 2024 –vol.11(3). -e176-e185. doi: 10.1016/S2352-3018(23)00272-2.

9. Brooks K.M., Sherman E.M., Egelund E.F., et al. Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?// Pharmacotherapy. – 2019. –vol.39(5). –p.576-598. doi: 10.1002/phar.2246.

10. Katz I.T., Maughan-Brown B. Improved life expectancy of people living with HIV: who is left behind? // Lancet HIV. – 2017. – vol.4(8).- e324-e326. doi: 10.1016/S2352-3018(17)30086-3.

11. Mugavero M.J., Napravnik S., Cole S.R., et al.; Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort Study. Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. //Clin Infect Dis. – 2011.- vol.53(9).-p.927-35. doi: 10.1093/cid/cir526.

12. Wang R., Haberlen S.A., Palella F.J. Jr. et al. Viremia copy-years and mortality among combination antire et al. troviral therapy-initiating HIV-positive individuals: how much viral load history is enough? // AIDS. – 2018. – vol.32(17). –p.2547-2556. doi: 10.1097/QAD.0000000000001986.

13. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes // Lancet. – 2004.-vol.364(9428). –p.51-62. doi: 10.1016/S0140-6736(04)16589-6.

14. Moore DM, Harris R, Lima V, et al. Antiretroviral Therapy Cohort Collaboration. Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. // J Acquir Immune Defic Syndr. – 2009. – vol.52(3). – p.357-63. doi: 10.1097/QAI.0b013e3181b62933.

15. Wada N, Jacobson L.P., Cohen M. et al. Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals // AIDS. – 2014. –vol.28(2). – p.257-65. doi: 10.1097/QAD.0000000000000078.

16. Palella, Frank & Baker, Rose & Moorman, et al. Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study // Journal of acquired immune deficiency syndromes. – 1999. – vol.. 43. – p. 27-34. doi:10.1097/01.qai.0000233310.90484.16.

17. Fontela C, Aguinaga A, Moreno-Iribas C et al. Trends and causes of mortality in a population-based cohort of HIV-infected adults in Spain: comparison with the general population // Sci Rep. – 2020. – vol.10(1).- p.8922. doi: 10.1038/s41598-020-65841-0.

18. Trickey A, McGinnis K, Gill MJ, et al. Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies // Lancet HIV. – 2024. – vol.11(3). – e176-185. doi: 10.1016/S2352-3018(23)00272-2.

19. Webel A.R., Schexnayder J., Cioe P.A., Zuñiga J.A. A Review of Chronic Comorbidities in Adults Living With HIV: State of the Science // J Assoc Nurses AIDS Care. – 2021. – vol.32(3). –p.322-346. doi: 10.1097/JNC.0000000000000240.

20. Landes M, van Lettow M, Bedell R, et al. Mortality and health outcomes in HIV-infected and HIV-uninfected mothers at 18-20 months postpartum in Zomba District, Malawi // PLoS One. – 2012. –vol.7(9). -e44396. doi: 10.1371/journal.pone.0044396.

21. Gao T.Y., Zhao L.K., Liu X., et al. Disease burden of AIDS in last 30-year period and its predicted level in next 25-years based on the global burden disease 2019 // BMC Public Health. – 2024. – vol.24(1). –p.2384. doi: 10.1186/s12889-024-19934-4.

22. Turrini G., Chan S.S., Klein P.W. et al. Assessing the health status and mortality of older people over 65 with HIV // PLoS One. – 2020. – vol.15(11). -e0241833. doi: 10.1371/journal.pone.0241833.

23. Croxford S, Kitching A, Desai S, et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort // Lancet Public Health. – 2017. –vol.2(1).- e35-46. doi: 10.1016/S2468-2667(16)30020-2.

24. Freiberg M.S., Chang C.C., Kuller L.H., et al. HIV infection and the risk of acute myocardial infarction // JAMA Intern Med. – 2013. – vol.173(8). –p.614-22. doi: 10.1001/jamainternmed.2013.3728.

25. Brugnaro, Pierluigi & Morelli, Erika & Cattelan, et al. Non-AIDS definings malignancies among human immunodeficiency virus-positive subjects: Epidemiology and outcome after two decades of HAART era // World journal of virology.- 2015 –vol.4. –p. 209-18. doi: 10.5501/wjv.v4.i3.209.

26. Croxford S.E., Martin V., Lucas S.B., et al. Recommendations for defining preventable HIV-related mortality for public health monitoring in the era of Getting to Zero: an expert consensus // Lancet HIV. – 2023. –vol.10(3). -e195-201. doi: 10.1016/S2352-3018(22)00363-0.

27. Santoro M.M., Di Carlo D., Armenia D., et al. Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice // Antivir Ther. – 2018. –vol.23(3). –p.249-257. doi: 10.3851/IMP3197.

28. Aldaz, P., Moreno-Iribas C., Egüés, N.et al. Mortality by causes in HIV-infected adults: comparison with the general population //BMC Public Health. -2011. –vol.11. –p. 300. https://doi.org/10.1186/1471-2458-11-300

29. Lang S., Mary-Krause M., Cotte L., et al. French Hospital Database on HIV-ANRS CO4. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population // AIDS. – 2010. – vol.24(8). –p.1228-30. doi: 10.1097/QAD.0b013e328339192f.

30. Fontela C., Aguinaga A., Moreno-Iribas et al. Trends and causes of mortality in a population-based cohort of HIV-infected adults in Spain: comparison with the general population // Sci Rep. – 2020. –vol.10(1). –p.8922. doi: 10.1038/s41598-020-65841-0.

31. Nishijima T., Inaba Y., Kawasaki Y., et al Mortality and causes of death in people living with HIV in the era of combination antiretroviral therapy compared with the general population in Japan //AIDS. – 2020. –vol.34(6) . –p. 913-921. doi: 10.1097/QAD.0000000000002498.

32. Zicari S., Sessa L., Cotugno N. et al. Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART // Viruses. – 2019. –vol. 11(3). –p.200. doi: 10.3390/v11030200.

33. Mafulu Y., Khumalo S., Williams V., et al. Causes of death in people living with HIV: Lessons from five health facilities in Eswatini // South Afr J HIV Med. – 2024. –vol.25(1). –p.1614. doi: 10.4102/sajhivmed.v25i1.1614.

34. Chen G.J., Sun H.Y., Chen L.Y., et al. Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens // Int J Antimicrob Agents. – 2022. –vol.60(3). –p.106631. doi: 10.1016/j.ijantimicag.2022.106631.